NuCana plc American Depositary Share
NCNA Real Time Price USDRecent trades of NCNA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NCNA holdings by institutional investors
Quarterly net insider trading by NCNA's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
NCNA Estimated quarterly lobbying spending
NCNA Revenue by Segment or Geography
New NCNA patent grants
-
Patent Title: Synthesis of phosphate derivatives Aug. 06, 2024
-
Patent Title: 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds Aug. 06, 2024
-
Patent Title: Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer Mar. 12, 2024
-
Patent Title: Synthesis of 3′-deoxyadenosine-5′-o-[phenyl(benzyloxy-l-alaninyl)]phosphate (nuc-738) Feb. 13, 2024
-
Patent Title: Formulations of phosphoramidate derivatives of nucleoside drugs Oct. 17, 2023
-
Patent Title: Formulation comprising a gemcitabine-prodrug Jul. 25, 2023
-
Patent Title: Gemcitabine prodrugs Apr. 18, 2023
-
Patent Title: Diastereoselective synthesis of phosphate derivatives Mar. 14, 2023
-
Patent Title: Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds Jan. 24, 2023
-
Patent Title: Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer Jan. 24, 2023
-
Patent Title: Synthesis of phosphate derivatives Aug. 16, 2022
-
Patent Title: Floxuridine synthesis Aug. 16, 2022
-
Patent Title: Cancer treatments Aug. 02, 2022
-
Patent Title: Crystalline form of gemcitabine Jul. 05, 2022
-
Patent Title: 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds Jun. 07, 2022
-
Patent Title: Process for preparing nucleoside prodrugs Jun. 22, 2021
-
Patent Title: Formulation comprising a gemcitabine-prodrug Jun. 22, 2021
-
Patent Title: Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer May. 04, 2021
-
Patent Title: Phosphoramidate nucleoside derivatives as anticancer agents Feb. 02, 2021
-
Patent Title: Formulation comprising a gemcitabine-prodrug Sep. 29, 2020
-
Patent Title: Methods of separating gemcitabine-phosphate diastereoisomers Jun. 02, 2020
-
Patent Title: Gemcitabine prodrugs May. 26, 2020
-
Patent Title: Combination therapy for cancer May. 26, 2020
-
Patent Title: 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds Feb. 25, 2020
-
Patent Title: Phosphoramidate compounds and methods of use Sep. 03, 2019
-
Patent Title: Formulation comprising a gemcitabine-prodrug Nov. 06, 2018
-
Patent Title: Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer Jul. 17, 2018
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NCNA from public contracts
Recent insights relating to NCNA
Recent picks made for NCNA stock on CNBC
ETFs with the largest estimated holdings in NCNA
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NCNA stock a Buy, Sell, or Hold?
- What is the price target for $NCNA stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NCNA stock?
- Who owns the most shares of $NCNA stock?
- What funds own $NCNA stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NCNA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.